Berek and Hacker's Gynecologic Oncology

 

Description:

 

Evidence-based, superbly illustrated, and easy to read, Berek & Hacker’s Gynecologic Oncology, Seventh Edition, remains your reference of choice for authoritative information on every aspect of gynecologic malignancies. Templated chapters provide quick access to guidance on everything from general principles through diagnosis and medical and surgical management. This fully revised edition offers the practical, state-of-the-art coverage you need when caring for women with preinvasive disease; ovarian, breast, uterine, cervical, vulvar, and vaginal cancers; and gestational trophoblastic disease.

• All chapters have been carefully updated to reflect the most current literature and practice recommendations.
• Presents summaries on signs and symptoms, staging, treatment, relevant basic science, genetics, and molecular issues.
• Key topics include preoperative care, laparoscopy, robotics, nutritional therapy, cancer in pregnancy, surgical techniques, symptom relief, and palliative care.
• Includes new chapters on genetics; cancer cell biology; and biologic, targeted, and immune therapies, as well as completely rewritten chapters on chemotherapy and communication skills.
• Features a new, visually appealing two-column design similar to Berek & Novak’s Gynecology, 16th Edition.
• Helps you visualize key concepts with full-color illustrations and drawings, pathology slides, and clinically relevant diagrams.
• Presents the knowledge and expertise of global leaders in gynecologic oncology, keeping you at the forefront of your field and preparing you for board exams.
• Clearly translates basic science to clinical practice, making it an excellent everyday resource for gynecologic oncologists and fellows, general gynecologists, and medical and radiation oncologists.

Enrich Your eBook Reading Experience

• Read directly on your preferred device(s), such as computer, tablet, or smartphone.
• Easily convert to audiobook, powering your content with natural language text-to-speech.

 

Table of Contents:

 

1.    Cover

2.    Title Page

3.    Copyright

4.    Dedication

5.    Contributors

6.    Foreword to the First Edition

7.    Preface

8.    Contents

9.    Section I: General Principles

10.  Chapter 1: Cancer Genetics

11.  Historic Perspective

12.  Genetic Changes

13.  Sporadic

14.  Hereditary

15.  Oncogenes

16.  Types of Oncogenes

17.  Tumor Suppressor Genes (Anti-Oncogenes)

18.  Epigenetic Changes

19.  Genetic Changes in Gynecologic Malignancies

20.  Endometrial Cancer

21.  Uterine Mesenchymal Tumors

22.  Ovarian Cancer

23.  Ovarian Sex Cord Stromal Tumors

24.  Cervical Cancer

25.  Vulvar Cancer

26.  Gestational Trophoblastic Disease

27.  Chapter 2: Cancer Cell Biology

28.  Cell Growth and Proliferation

29.  Oncogenes

30.  Tumor Suppressor Genes

31.  DNA Repair

32.  DNA Damage Response Defects and Synthetic Lethality to Enhance Efficacy of Cancer Therapy

33.  Cell Death Pathways

34.  Autophagy

35.  Apoptosis

36.  Necrosis

37.  Cancer Stem Cells

38.  Cellular Senescence

39.  Cell Metabolism

40.  Hormone Metabolism

41.  Post-translational Modifications

42.  Cell Invasion and Metastasis

43.  Epithelial-to-Mesenchymal Transition

44.  Tumor Microenvironment

45.  Immune Checkpoints

46.  Angiogenesis

47.  Biomarkers

48.  Tumor Markers

49.  Chapter 3: Biologic, Targeted, and Immune Therapy

50.  Inhibitors of Growth Factor Receptors

51.  EGFR Inhibitors

52.  EGFR Inhibitors—Small Molecules

53.  EGFR Inhibitors—Monoclonal Antibodies

54.  Her2/Neu Inhibitors

55.  Her2/Neu Inhibitors—Small Molecules

56.  Her2/Neu Inhibitors—Monoclonal Antibodies

57.  PDGFR Inhibitors—Monoclonal Antibodies

58.  Inhibitors of Angiogenesis

59.  VEGFR Inhibitors—Small Molecules

60.  VEGFR Inhibitors—Monoclonal Antibodies

61.  Inhibitors of Other Intracellular Kinases

62.  Small Molecules

63.  Braf (Rapidly Activated Fibrosarcoma) Inhibitors

64.  MEK1-2 (MAPK/ERK Kinase) Inhibitors

65.  CDK 4-6 (Cyclin-Dependent Kinases 4-6) Inhibitors

66.  ALK (Anaplastic Lymphoma Kinase) Inhibitors

67.  PI-3K (Phosphatidylinositol 3-Kinase) Inhibitors

68.  mTOR (Mammalian Target of Rapamycin) Inhibitors

69.  Inhibitors of DNA Repair

70.  PARP (Poly-ADP Ribose-Polymerase) Inhibitors

71.  Immunotherapy

72.  Cytokines

73.  Monoclonal Antibodies

74.  Immune Checkpoint Inhibitors

75.  Anti–PD-1 (Programmed Cell Death Receptor-1) Antibodies

76.  Anti–PD-L1 (Programmed Cell Death Receptor Ligand-1) Antibodies

77.  Therapeutic Cancer Vaccines

78.  Cell-Based Vaccines

79.  Glycan-Based Vaccines

80.  Adoptive Cell Therapy

81.  Chapter 4: Chemotherapy

82.  General Principles

83.  Tumor Growth and Chemotherapy

84.  Differential Sensitivity

85.  Therapeutic Index

86.  Brief History of Chemotherapy

87.  Biologic Factors Influencing Treatment

88.  Cell Kinetic Concepts

89.  Cancer Cell Growth

90.  Principles of Chemotherapy

91.  Neoadjuvant Chemotherapy

92.  Hyperthermic Intraperitoneal Chemotherapy

93.  Antibody–Drug Conjugates

94.  Chemotherapy in Pregnancy

95.  Drug Resistance

96.  Excretion

97.  Drug Interactions

98.  Combination Chemotherapy

99.  Clinical Benefit

100.               RECIST Criteria

101.               Dose Adjustment

102.               Carboplatin Dose Calculation

103.               Toxicities and Their Management

104.               Antineoplastic Drugs

105.               Alkylating Agents

106.               Antitumor Antibiotics and Topoisomerase Inhibitors

107.               Antimetabolites

108.               Plant Alkaloids (Mitotic Spindle Agents)

109.               Chapter 5: Radiation Therapy

110.               Radiation Biology

111.               Radiation Damage and Repair

112.               Cell Survival Curves

113.               Fractionation

114.               Dose-Rate Effect

115.               The Four Rs

116.               Treatment Strategies for Overcoming Radioresistance of Hypoxic Cells

117.               Linear-Energy Transfer and Relative Biologic Effectiveness

118.               Hyperthermia

119.               Interactions between Radiation and Drugs

120.               Radiation Therapy and the Immune System

121.               Therapeutic Ratio

122.               Effects of Radiation on Normal Tissues

123.               Scoring of Late Complications of Radiation Therapy

124.               Treatment Strategies to Exploit Differences Between Tumor and Normal Tissue in the Response to Fractionated Radiation Therapy

125.               Combinations of Surgery and Radiation Therapy

126.               Physical Principles

127.               Ionizing Radiations Used in Therapy

128.               Interactions of Radiation With Matter

129.               Measurement of Absorbed Dose

130.               Inverse Square Law

131.               Radiation Techniques

132.               External Beam Irradiation

133.               Brachytherapy

134.               Palliation

135.               Chapter 6: Pathology

136.               Cervix

137.               Squamous Lesions of the Cervix

138.               Human Papilloma Virus

139.               Cervicovaginal Cytology—Pap Testing

140.               Glandular Lesions of the Cervix

141.               Mesenchymal Tumors

142.               Vagina

143.               Squamous Lesions of the Vagina

144.               Glandular Lesions of the Vagina

145.               Fibroepithelial Stromal Polyp

146.               Sarcoma Botryoides

147.               Melanoma

148.               Postoperative Spindle Cell Nodule

149.               Vulva

150.               Squamous Cell Lesions of the Vulva

151.               Other Vulvar Lesions

152.               Mesenchymal Tumors

153.               Aggressive Angiomyxoma

154.               Melanocytic Tumors

155.               Uncommon Neoplasms

156.               Uterine Corpus

157.               Endometrial Neoplasms

158.               Endometrial Carcinoma

159.               Histologic Types

160.               Histologic Grading of Endometrioid Carcinoma

161.               Pathologic Staging of Endometrial Carcinoma

162.               Mesenchymal Neoplasms

163.               Uterine Tumor Resembling Ovarian Sex Cord–Stromal Tumor

164.               Endometrial Stromal Tumors

165.               Undifferentiated Uterine Sarcoma

166.               Other Uterine Mesenchymal Tumors

167.               Mixed Müllerian Neoplasms

168.               Adenofibroma

169.               Atypical Polypoid Adenomyoma

170.               Adenosarcoma

171.               Carcinosarcoma

172.               Ovary

173.               Ovarian Epithelial Tumors

174.               Sex Cord–Stromal Tumors

175.               Germ Cell Tumors

176.               Embryonal Carcinoma

177.               Miscellaneous Ovarian Tumors

178.               Secondary Tumors of the Ovary—Metastases

179.               Nonneoplastic Lesions of the Ovary

180.               Luteinized Ovarian Conditions

181.               Fallopian Tube

182.               Primary Tubal Carcinoma

183.               Adenomatoid Tumor

184.               Gestational Trophoblastic Disease

185.               Hydatidiform Mole

186.               Choriocarcinoma

187.               Placental Site Trophoblastic Tumor

188.               Chapter 7: Epidemiology and Biostatistics

189.               Descriptive Statistics

190.               Incidence

191.               Prevalence

192.               Cancer Survival

193.               Etiologic Studies

194.               Case–Control Study

195.               Cohort Studies

196.               Statistical Inference and Validity

197.               Statistical Inference

198.               Statistical Distributions and Tests

199.               Validity

200.               Other Criteria for Judging an Epidemiologic Study

201.               Cancer Risk and Prevention

202.               Cervical Cancer

203.               Endometrial Cancer

204.               Ovarian Cancer

205.               Other Gynecologic Neoplasms

206.               Cancer Prevention

207.               Secondary Prevention

208.               Test Definitions

209.               Sensitivity

210.               Specificity

211.               Predictive Value

212.               Screening Strategies

213.               Section II: Disease Sites

214.               Chapter 8: Preinvasive Disease

215.               Cervix

216.               Classification of Preinvasive Cervical Disease

217.               Understanding the Cervical Transformation Zone

218.               IFCPC Colposcopic Terminology of the Cervix, Vagina, and Vulva

219.               Systematic Approach to Colposcopy

220.               Indications for Colposcopy

221.               Human Papillomaviruses and Cervical Neoplasia

222.               Human Papillomavirus Vaccines

223.               The WHO Initiative for the Elimination of Cervical Cancer as a Public Health Problem

224.               Screening for Cervical Neoplasia

225.               Treatment of Cervical Intraepithelial Neoplasia

226.               Treatment Modalities

227.               Vagina

228.               Classification of Vaginal Intraepithelial Neoplasia

229.               Clinical Profile

230.               Diagnosis

231.               Treatment of High-Grade Vaginal Intraepithelial Neoplasia

232.               Vulva and Perianal Area

233.               Classification

234.               Paget Disease

235.               Clinical Profile of High-Grade Vulvar Intraepithelial Neoplasia (uVIN)

236.               Diagnosis

237.               Natural History of High-Grade Vulvar Intraepithelial Neoplasia

238.               Differentiated Vulvar Intraepithelial Neoplasia (dVIN)

239.               Treatment of High-Grade Vulvar Intraepithelial Neoplasia

240.               HPV Vaccination

241.               Multicentric Lower Genital Tract Neoplasia

242.               Chapter 9: Cervical Cancer

243.               Diagnosis

244.               Symptoms

245.               Signs

246.               Biopsy

247.               Colposcopy for Invasive Cancer

248.               Staging

249.               Noninvasive Diagnostic Studies

250.               Surgical Staging

251.               Patterns of Spread

252.               Direct Infiltration

253.               Lymphatic Spread

254.               Hematogenous Spread

255.               Treatment

256.               Microinvasive Carcinoma

257.               2018 FIGO Stages IB1, IB2, and Early-Stage IIA1 Cervical Cancer

258.               Stage IB3 Cervical Carcinoma

259.               Prognostic Factors for Stages IB to IIA

260.               Stages IIB to IVA Disease

261.               Nonsquamous Histologic Types

262.               Adenocarcinoma

263.               Adenosquamous Carcinoma

264.               Glassy Cell Carcinoma

265.               Adenoma Malignum (Minimum Deviation Adenocarcinoma)

266.               Adenoid Cystic Carcinoma

267.               Adenoid Basal Carcinoma

268.               Clear Cell Adenocarcinoma

269.               Villoglandular Papillary Adenocarcinoma

270.               Small-Cell, including Small-Cell Neuroendocrine Carcinoma

271.               Large-Cell Neuroendocrine Carcinoma

272.               Serous Carcinoma

273.               Sarcoma

274.               Lymphoma

275.               Verrucous Carcinoma

276.               Melanoma

277.               Metastatic Carcinoma

278.               Cancer of the Cervical Stump

279.               Invasive Cancer Found after Simple Hysterectomy

280.               Coexistent Pelvic Mass

281.               Cervical Bleeding

282.               Recurrent Cervical Cancer

283.               Radical Hysterectomy for Recurrence

284.               Chemotherapy

285.               Chapter 10: Uterine Cancer

286.               Prevention of Disease and Screening of Asymptomatic Women

287.               Clinical Features

288.               Symptoms

289.               Signs

290.               Diagnosis

291.               Preoperative Investigations

292.               Staging

293.               Spread Patterns

294.               Prognostic Variables

295.               Age

296.               Histologic Type

297.               Histologic Grade and Myometrial Invasion

298.               Vascular Space Invasion

299.               Results of Peritoneal Cytology

300.               Hormone Receptor Status

301.               Nuclear Grade

302.               Tumor Size

303.               DNA Ploidy and Other Biologic Markers

304.               Body Mass Index

305.               Method of Treatment

306.               Endometrial Hyperplasia

307.               Diagnosis

308.               Treatment

309.               Treatment of Endometrial Cancer

310.               Stage I and Stage II Occult

311.               Clinical Stage II

312.               Surgical Stage IIIA

313.               Surgical Stage IIIB

314.               Surgical Stage IVA

315.               Surgical Stage IVB

316.               Special Clinical Circumstances

317.               Recurrent Endometrial Cancer

318.               Isolated Vaginal Recurrence

319.               Nodal Recurrence

320.               Systemic Recurrence: Role of Surgery

321.               Role of Hormonal Therapy

322.               Role of Cytotoxic Chemotherapy

323.               Immunotherapy

324.               Hormone Replacement Therapy

325.               Prognosis

326.               Uterine Sarcomas

327.               Smooth Muscle Tumors

328.               Endometrial Stromal Tumors

329.               Adenosarcoma

330.               Carcinosarcoma

331.               Chapter 11: Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

332.               Classification

333.               Pathology

334.               Clinical Features

335.               Epidemiology

336.               Prevention

337.               Screening

338.               Genetic Risk for Epithelial Ovarian Cancer

339.               Symptoms

340.               Signs

341.               Diagnosis

342.               Patterns of Spread

343.               Prognostic Factors

344.               Pathologic Factors

345.               Clinical Factors

346.               Initial Surgery for Ovarian Cancer

347.               Staging

348.               Early-Stage Ovarian Cancer

349.               Advanced-Stage Ovarian Cancer

350.               Adjuvant Chemotherapy

351.               Stage I Low-Risk Ovarian Cancer

352.               Stage I High-Risk Ovarian Cancer

353.               Chemotherapy and Molecular Targeted Therapies

354.               Treatment Assessment

355.               Tumor Markers

356.               Radiologic Assessment

357.               Secondary Therapy

358.               Secondary Cytoreduction

359.               Chemotherapy for Recurrent Ovarian Cancer

360.               Intestinal Obstruction

361.               Chapter 12: Germ Cell and Nonepithelial Ovarian Cancers

362.               Germ Cell Malignancies

363.               Classification

364.               Epidemiology

365.               Clinical Features

366.               Dysgerminoma

367.               Immature Teratomas

368.               Endodermal Sinus Tumor

369.               Rare Germ Cell Tumors of the Ovary

370.               Mixed Germ Cell Tumors

371.               Surveillance for Stage I Ovarian Germ Cell Tumors

372.               Late Effects of Treatment of Malignant Germ Cell Tumors of the Ovary

373.               Sex-Cord–Stromal Tumors

374.               Granulosa–Stromal-Cell Tumors

375.               Sertoli–Leydig Tumors

376.               Uncommon Ovarian Cancers

377.               Lipoid Cell Tumors

378.               Sarcomas

379.               Small Cell Carcinomas of Hypercalcemic Type

380.               Metastatic Tumors

381.               Gynecologic Primary

382.               Nongynecologic Primary

383.               Krukenberg Tumor

384.               Other Gastrointestinal Tumors

385.               Melanoma

386.               Carcinoid

387.               Lymphoma and Leukemia

388.               Chapter 13: Vulvar Cancer

389.               Etiology of Invasive Squamous Cell Carcinoma

390.               Paget Disease of the Vulva

391.               Type 1 Paget Disease

392.               Invasive Paget Disease

393.               Invasive Vulvar Cancer

394.               Squamous Cell Carcinoma

395.               Melanoma

396.               Bartholin Gland Carcinoma

397.               Other Vulvar Adenocarcinomas

398.               Basal Cell Carcinoma

399.               Verrucous Carcinoma

400.               Vulvar Sarcoma

401.               Lymphoma

402.               Endodermal Sinus Tumor

403.               Merkel Cell Carcinoma

404.               Secondary Vulvar Tumors

405.               Chapter 14: Vaginal Cancer

406.               Primary Vaginal Tumors

407.               Squamous Cell Carcinoma

408.               Adenocarcinoma

409.               Small Cell Carcinoma

410.               Verrucous Carcinoma

411.               Vaginal Melanoma

412.               Vaginal Sarcoma

413.               Germ Cell Tumors

414.               Carcinoma of the Female Urethra

415.               Prognosis

416.               Malignant Melanoma of the Urethra

417.               Chapter 15: Gestational Trophoblastic Disease

418.               Hydatidiform Mole

419.               Complete Versus Partial Hydatidiform Mole

420.               Clinical Features

421.               Natural History

422.               Diagnosis

423.               Treatment

424.               Follow-Up

425.               Gestational Trophoblastic Neoplasia

426.               Nonmetastatic Disease

427.               Metastatic Disease and Choriocarcinoma

428.               Staging

429.               Prognostic Scoring System

430.               Diagnostic Evaluation

431.               Management of Gestational Trophoblastic Neoplasia

432.               Chemotherapy

433.               Single-Agent Chemotherapy

434.               Combination Chemotherapy

435.               Subsequent Pregnancies

436.               Chapter 16: Breast Disease

437.               Detection

438.               Physical Examination

439.               Breast Imaging

440.               Benign Breast Conditions

441.               Fibrocystic Change

442.               Benign Tumors

443.               Breast Cancer

444.               Predisposing Factors

445.               Diagnosis

446.               Pathology and Natural History

447.               Biology of Breast Cancer

448.               Staging

449.               Treatment of Breast Cancer

450.               Surgery

451.               Other Breast Diseases

452.               Future Fertility

453.               Prognosis

454.               Chemoprevention

455.               Chapter 17: Cancer in Pregnancy

456.               Diagnosis

457.               Staging

458.               Interdisciplinary Review

459.               Surgery During Pregnancy

460.               Radiation During Pregnancy

461.               Chemotherapy During Pregnancy

462.               Pharmacokinetics

463.               Transplacental Passage of Chemotherapeutic Drugs

464.               Obstetric Management

465.               Fetal Outcome After Antenatal Exposure to Chemotherapy

466.               Management of Cervical Intraepithelial Neoplasia in Pregnancy

467.               Management of Cancer in Pregnancy

468.               Invasive Cervical Cancer

469.               Breast Cancer

470.               Ovarian Cancer

471.               Vulvar Cancer

472.               Malignant Melanoma

473.               Hematologic Malignancy

474.               Section III: Medical and Surgical Topics

475.               Chapter 18: Preoperative Evaluation, Medical Management, and Critical Care

476.               Preoperative Evaluation

477.               Cardiovascular

478.               Pulmonary

479.               Diabetes Mellitus

480.               Thyroid Disorders

481.               Corticosteroids

482.               Thromboembolic Disease Prevention

483.               Preoperative Testing

484.               Prevention of Surgical Site Infection

485.               Postoperative Management

486.               Cardiovascular

487.               Respiratory Failure

488.               Renal Insufficiency, Fluids, and Electrolytes

489.               Nutrition

490.               Blood Replacement

491.               Clotting Disorders

492.               Adverse Effects of Blood Transfusions

493.               Venous Thromboembolism

494.               Postoperative Fever

495.               Infection

496.               Chapter 19: Nutritional Therapy

497.               Normal Body Metabolism

498.               Calories

499.               Dietary Calories

500.               Body Stores

501.               Metabolism During Starvation

502.               Malnutrition

503.               Risk Factors

504.               Etiology of Malnutrition in the Cancer Patient

505.               Definitions and Classification

506.               Diagnosis

507.               Nutritional Support

508.               Caloric Requirements

509.               Provision of Nutritional Support

510.               Chapter 20: Surgical Techniques

511.               Central Lines

512.               Subclavian Venous Catheterization

513.               Jugular Venous Catheterization

514.               Dynamic Ultrasonic Technique

515.               Semipermanent and Permanent Lines

516.               Intraperitoneal Catheters

517.               Incisions for Laparotomy

518.               Vertical Incisions

519.               Transverse Incisions

520.               Incisional Closure

521.               Intestinal Operations

522.               Enhanced Recovery After Surgery (ERAS)

523.               Minor Intestinal Operations

524.               Major Intestinal Operations

525.               Intestinal Staplers

526.               Stapling Technique

527.               Upper Abdominal Cytoreduction

528.               Omentectomy

529.               Splenectomy

530.               Liver Mobilization, Diaphragm Stripping, and Resection

531.               Urinary Tract Operations

532.               Cystoscopy

533.               Cystostomy

534.               Ureteric Obstruction

535.               Ureteral Reanastomosis (Ureteroureterostomy)

536.               Ureteroneocystostomy

537.               Transureteroureterostomy

538.               Permanent Urinary Diversion

539.               Reconstructive Operations

540.               Grafts

541.               Vaginal Reconstruction

542.               Vulvar and Perineal Reconstruction

543.               Pelvic Floor Reconstruction

544.               Chapter 21: Laparoscopy

545.               Laparoscopic Pelvic and Para-aortic Lymphadenectomy

546.               Infrarenal Para-aortic Lymphadenectomy

547.               Indications for Laparoscopic Surgery

548.               Endometrial Cancer

549.               Cervical Cancer

550.               Ovarian Cancer

551.               Complications

552.               Technique

553.               Preoperative Preparation

554.               Operative Approach

555.               Postoperative Management

556.               Chapter 22: Robotics

557.               Robotic Surgery: Development of a New Operating System

558.               Robotic System: Da Vinci Surgical System®

559.               Robotic System Components

560.               Patient Positioning, Docking, and Instrumentation

561.               Other Robotic Systems Currently Available or Under Development

562.               Application of Robotics to Gynecologic Cancers

563.               Endometrial Cancer

564.               Cervical Cancer

565.               Ovarian Cancer

566.               Pelvic Exenteration

567.               Sentinel Lymph Nodes

568.               Complications Specific to Robotic Surgery

569.               Cost of Robotic Surgery

570.               Training and Education During the Robotic Era

571.               Future Developments in Robotics

572.               Summary

573.               Chapter 23: Pelvic Exenteration

574.               History of Exenteration

575.               Indications

576.               Patient Selection

577.               Neoadjuvant Chemotherapy

578.               Preoperative Patient Preparation

579.               Operative Technique

580.               Anterior Exenteration

581.               Supralevator Total Exenteration

582.               Total Exenteration with Perineal Phase

583.               Posterior Exenteration

584.               Low Rectal Anastomosis during Pelvic Exenteration

585.               Urinary Diversion

586.               Postoperative Care

587.               Complications

588.               Gastrointestinal Complications

589.               Urinary Tract Complications

590.               Results

591.               Intraoperative Radiation Therapy

592.               Quality of Life

593.               Section IV: Quality of Life

594.               Chapter 24: Communication Skills

595.               Why Shared Understanding Matters

596.               Who is Responsible for Discussing Goals of Medical Treatment?

597.               Barriers to Communication Around Treatment Goals

598.               Are Communication Skills Around Serious Illness Teachable?

599.               Strategies at the Start

600.               Discussing Prognosis

601.               Patient-Centered Cancer Treatment Plans: An Evolving Reference Document for Patients

602.               An Ongoing Conversation

603.               Balancing Hope and Honesty

604.               Responding to Emotion

605.               Best Case and Worst Case: A Tool for High-Stakes Surgical Decisions

606.               Breaking Bad News

607.               Making a Recommendation

608.               Code Status

609.               Total Parenteral Nutrition

610.               When More Chemotherapy May Not Be the Answer

611.               Involving Family Members

612.               Involving a Palliative Medicine Team

613.               Differences Between Palliative Medicine and Hospice

614.               Summary

615.               Chapter 25: Symptom Relief and Palliative Care

616.               Practical Aspects of Palliative Care

617.               Assessment

618.               Clinical Decision Making

619.               Evaluation of Outcomes

620.               Discussing Prognosis

621.               Symptoms and Their Relief

622.               Pain Management

623.               Special Considerations in Pain Management

624.               Gastrointestinal Symptoms

625.               Respiratory Symptoms

626.               Urinary Tract Symptoms

627.               Edema

628.               Fatigue

629.               Hypercalcemia

630.               Wound Care

631.               Family Caregivers

632.               Care of the Patient Close to Death

633.               Advance Care Planning

634.               Ethical Issues

635.               A Final Note

636.               Chapter 26: Psychological Issues

637.               Responses to Gynecologic Screening and Early Diagnostic Procedures

638.               Screening

639.               Colposcopy

640.               Consultation With a Gynecologic Oncologist

641.               Responses to Diagnosis and the Importance of Screening for Psychological Distress and Sexual Function

642.               Biobehavioral

643.               Screening for Depressive and Anxiety Symptoms

644.               Assessment of Sexual Functioning

645.               Responses to Treatment

646.               Surgery

647.               Radiation Therapy

648.               Chemotherapy

649.               Immunotherapy and Targeted Therapy

650.               Responses to Being “Off Treatment”

651.               Responses of Survivors

652.               Recurrence and Progressive Disease

653.               Interventions for Psychological Morbidity

654.               Informational Needs

655.               Reducing Stress, Enhancing Coping, and Treating Anxiety and Depression

656.               Sexuality Morbidity and Related Interventions

657.               Sexual Morbidity

658.               Assessment of Sexual Morbidity

659.               Interventions for Specific Problems

660.               Sexual Therapy

661.               Conclusion

662.               Index

 

 

An aparitie	25 July 2020
Autor	Jonathan S. Berek, Neville F. Hacker
Dimensiuni	21.84 x 3.56 x 28.19 cm
Editura	Elsevier
Format	Hardcover
ISBN	9781975142643
Limba	Engleza
Nr pag	975